# Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

> **NCT05899829** · PHASE1 · COMPLETED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 42 (actual)

## Conditions studied

- Cough
- Healthy

## Interventions

- **DRUG:** Camlipixant
- **DRUG:** Rabeprazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT05899829
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-21
- **Primary completion:** 2023-08-08
- **Final completion:** 2023-08-08
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05899829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05899829, "Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT05899829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*